{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T04:07:03Z","timestamp":1746677223967,"version":"3.40.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00347-024-02169-4","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:43:32Z","timestamp":1736865812000},"page":"357-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neue systemische Therapieans\u00e4tze beim prim\u00e4ren Lymphom der Orbita und der okul\u00e4ren Adnexe","New systemic treatment approach for primary lymphoma of the orbit and the ocular adnexa"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-6714","authenticated-orcid":false,"given":"Constantin","family":"Niederau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philomena Alice","family":"Wawer Matos Reimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Rokohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"2169_CR1","doi-asserted-by":"publisher","unstructured":"Incidence of orbital, conjunctival and lacrimal gland malignant tumors in USA from Surveillance, Epidemiology and End Results, 1973\u20132009. Int J Ophthalmol 2016; https:\/\/doi.org\/10.18240\/ijo.2016.12.18","DOI":"10.18240\/ijo.2016.12.18"},{"key":"2169_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s00347-022-01650-2","volume":"119","author":"F Fend","year":"2022","unstructured":"Fend\u00a0F, Bonzheim\u00a0I, Kakkassery\u00a0V et\u00a0al (2022) Lymphome des Auges und seiner Adnexe: Moderne pathologische Diagnostik und systemische Therapie. Ophthalmol 119:664\u2013674. https:\/\/doi.org\/10.1007\/s00347-022-01650-2","journal-title":"Ophthalmol"},{"key":"2169_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1586\/eop.11.15","volume":"6","author":"R Moslehi","year":"2011","unstructured":"Moslehi\u00a0R, Schymura\u00a0MJ, Nayak\u00a0S et\u00a0al (2011) Ocular adnexal non-Hodgkin\u2019s lymphoma: a\u00a0review of epidemiology and risk factors. Expert Rev Ophthalmol 6:181\u2013193. https:\/\/doi.org\/10.1586\/eop.11.15","journal-title":"Expert Rev Ophthalmol"},{"key":"2169_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ohc.2004.11.001","volume":"18","author":"D Bardenstein","year":"2005","unstructured":"Bardenstein\u00a0D (2005) Ocular Adnexal Lymphoma: Classification, Clinical Disease, and Molecular Biology. Ophthalmol Clin N Am 18:187\u2013197. https:\/\/doi.org\/10.1016\/j.ohc.2004.11.001","journal-title":"Ophthalmol Clin N Am"},{"key":"2169_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12308-020-00424-6","volume":"14","author":"JA Ferry","year":"2021","unstructured":"Ferry\u00a0JA, Fung\u00a0CY, Lucarelli\u00a0MJ et\u00a0al (2021) Ocular adnexal lymphoma: long-term outcome, patterns of failure and prognostic factors in 174 patients. J\u00a0Hematop 14:41\u201352. https:\/\/doi.org\/10.1007\/s12308-020-00424-6","journal-title":"J Hematop"},{"key":"2169_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00347-014-3205-y","volume":"112","author":"V Kakkassery","year":"2015","unstructured":"Kakkassery\u00a0V, St\u00fcbiger\u00a0N, Adamietz\u00a0IA et\u00a0al (2015) Lymphome der okul\u00e4ren Adnexe. Ophthalmol 112:210\u2013216. https:\/\/doi.org\/10.1007\/s00347-014-3205-y","journal-title":"Ophthalmol"},{"key":"2169_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/cncr.22843","volume":"110","author":"A Husain","year":"2007","unstructured":"Husain\u00a0A, Roberts\u00a0D, Pro\u00a0B et\u00a0al (2007) Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 110:809\u2013815. https:\/\/doi.org\/10.1002\/cncr.22843","journal-title":"Cancer"},{"key":"2169_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00347-019-01020-5","volume":"117","author":"V Kakkassery","year":"2020","unstructured":"Kakkassery\u00a0V, J\u00fcnemann\u00a0AM, Bechrakis\u00a0NE et\u00a0al (2020) Lymphom am Auge: Pr\u00e4zise Diagnostik und Klassifikation als Schl\u00fcssel einer erfolgreichen personalisierten Therapie. Ophthalmol 117:499\u2013507. https:\/\/doi.org\/10.1007\/s00347-019-01020-5","journal-title":"Ophthalmol"},{"key":"2169_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.survophthal.2018.08.002","volume":"64","author":"TG Olsen","year":"2019","unstructured":"Olsen\u00a0TG, Heegaard\u00a0S (2019) Orbital lymphoma. Surv Ophthalmol 64:45\u201366. https:\/\/doi.org\/10.1016\/j.survophthal.2018.08.002","journal-title":"Surv Ophthalmol"},{"key":"2169_CR10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s00761-020-00854-y","volume":"26","author":"M Zschoche","year":"2020","unstructured":"Zschoche\u00a0M, Emmert\u00a0S, Von Bubnoff\u00a0N et\u00a0al (2020) Augenbefall und Systemerkrankung \u2013 periokul\u00e4re und intraokul\u00e4re Lymphome. Onkol 26:1056\u20131064. https:\/\/doi.org\/10.1007\/s00761-020-00854-y","journal-title":"Onkol"},{"key":"2169_CR11","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00347-021-01568-1","volume":"119","author":"M Simon","year":"2022","unstructured":"Simon\u00a0M, Wawer Matos\u00a0PA, Meinel\u00a0J et\u00a0al (2022) Klinisches Vorgehen bei periokul\u00e4ren Lymphomen. Ophthalmol 119:686\u2013691. https:\/\/doi.org\/10.1007\/s00347-021-01568-1","journal-title":"Ophthalmol"},{"key":"2169_CR12","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio\u00a0R, Amador\u00a0C, Anagnostopoulos\u00a0I et\u00a0al (2022) The 5th\u00a0edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"key":"2169_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000499845","volume":"5","author":"VA White","year":"2019","unstructured":"White\u00a0VA (2019) Understanding and Classification of Ocular Lymphomas. Ocul Oncol Pathol 5:379\u2013386. https:\/\/doi.org\/10.1159\/000499845","journal-title":"Ocul Oncol Pathol"},{"key":"2169_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00347-021-01359-8","volume":"119","author":"V Sch\u00f6neberger","year":"2022","unstructured":"Sch\u00f6neberger\u00a0V, Meyer\u00a0FI, Lohneis\u00a0P et\u00a0al (2022) Follikul\u00e4res Lymphom der Bindehaut mit aggressiv transformiertem systemischem Befall. Ophthalmol 119:388\u2013391. https:\/\/doi.org\/10.1007\/s00347-021-01359-8","journal-title":"Ophthalmol"},{"key":"2169_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/bjophthalmol-2020-315875","volume":"105","author":"M Kwon","year":"2021","unstructured":"Kwon\u00a0M, Lee\u00a0JS, Lee\u00a0C et\u00a0al (2021) Prognostic factors for relapse and survival among patients with ocular adnexal lymphoma: validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification. Br J Ophthalmol 105:279\u2013284. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-315875","journal-title":"Br J Ophthalmol"},{"key":"2169_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3322\/canjclin.55.6.368","volume":"55","author":"JO Armitage","year":"2005","unstructured":"Armitage\u00a0JO (2005) Staging Non-Hodgkin Lymphoma. CA Cancer J Clin 55:368\u2013376. https:\/\/doi.org\/10.3322\/canjclin.55.6.368","journal-title":"CA Cancer J Clin"},{"key":"2169_CR17","first-page":"218","volume":"153","author":"K Musshoff","year":"1977","unstructured":"Musshoff\u00a0K (1977) Clinical staging classification of non-Hodgkin\u2019s lymphomas (author\u2019s transl). Strahlentherapie 153:218\u2013221","journal-title":"Strahlentherapie"},{"key":"2169_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2147\/opth.s5828","volume":"3","author":"VML Cohen","year":"2009","unstructured":"Cohen\u00a0VML (2009) Treatment options for ocular adnexal lymphoma (OAL). Clin Ophthalmol Auckl Nz 3:689\u2013692. https:\/\/doi.org\/10.2147\/opth.s5828","journal-title":"Clin Ophthalmol Auckl Nz"},{"key":"2169_CR19","volume-title":"Mantelzell-Lymphom. Onkopedia Leitlin","author":"M Dreyling","year":"2023","unstructured":"Dreyling\u00a0M, Buske\u00a0C, Cairoli\u00a0A et\u00a0al (2023) Mantelzell-Lymphom. Onkopedia Leitlin"},{"key":"2169_CR20","volume-title":"Diffuses gro\u00dfzelliges B-Zell-Lymphom. Onkopedia Leitlin","author":"G Lenz","year":"2024","unstructured":"Lenz\u00a0G, Chapuy\u00a0B, Gla\u00df\u00a0B et\u00a0al (2024) Diffuses gro\u00dfzelliges B\u2011Zell-Lymphom. Onkopedia Leitlin"},{"key":"2169_CR21","volume-title":"Extranodales Marginalzonen-Lymphom (MALT LYMPHOM). Onkopedia Leitlin","author":"M Raderer","year":"2023","unstructured":"Raderer\u00a0M, Buske\u00a0C, Dreyling\u00a0M et\u00a0al (2023) Extranodales Marginalzonen-Lymphom (MALT LYMPHOM). Onkopedia Leitlin"},{"key":"2169_CR22","volume-title":"Follikul\u00e4res Lymphom. Onkopedia Leitlin","author":"C Buske","year":"2023","unstructured":"Buske\u00a0C, Dreyling\u00a0M, Herfarth\u00a0K et\u00a0al (2023) Follikul\u00e4res Lymphom. Onkopedia Leitlin"},{"key":"2169_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ophtha.2017.05.037","volume":"125","author":"MT Yen","year":"2018","unstructured":"Yen\u00a0MT, Bilyk\u00a0JR, Wladis\u00a0EJ et\u00a0al (2018) Treatments for Ocular Adnexal Lymphoma. Ophthalmology 125:127\u2013136. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.037","journal-title":"Ophthalmology"},{"key":"2169_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.2021.278755","volume":"107","author":"CY Cheah","year":"2022","unstructured":"Cheah\u00a0CY, Zucca\u00a0E, Rossi\u00a0D et\u00a0al (2022) Marginal zone lymphoma: present status and future perspectives. Haematologica 107:35\u201343. https:\/\/doi.org\/10.3324\/haematol.2021.278755","journal-title":"Haematologica"},{"key":"2169_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5045\/br.2022.2022054","volume":"57","author":"SH Jeong","year":"2022","unstructured":"Jeong\u00a0SH (2022) Treatment of indolent lymphoma. Blood Res 57:120\u2013S129. https:\/\/doi.org\/10.5045\/br.2022.2022054","journal-title":"Blood Res"},{"key":"2169_CR26","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger\u00a0JA, Tedeschi\u00a0A, Barr\u00a0PM et\u00a0al (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N\u00a0Engl J Med 373:2425\u20132437. https:\/\/doi.org\/10.1056\/NEJMoa1509388","journal-title":"N Engl J Med"},{"key":"2169_CR27","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.23.00033","volume":"41","author":"AJ Davies","year":"2023","unstructured":"Davies\u00a0AJ, Barrans\u00a0S, Stanton\u00a0L et\u00a0al (2023) Differential Efficacy From the Addition of Bortezomib to R\u2011CHOP in Diffuse Large B\u2011Cell Lymphoma According to the Molecular Subgroup in the REMoDL\u2011B Study With a\u00a05-Year Follow-Up. J\u00a0Clin Oncol 41:2718\u20132723. https:\/\/doi.org\/10.1200\/JCO.23.00033","journal-title":"J Clin Oncol"},{"key":"2169_CR28","unstructured":"Ponzoni M, Bongiovanni L Ocular adnexal marginal zone lymphoma (OAMZL). Atlas Genet Cytogenet Oncol Haematol"},{"key":"2169_CR29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/annonc\/mdq416","volume":"22","author":"A Conconi","year":"2011","unstructured":"Conconi\u00a0A, Martinelli\u00a0G, Lopez-Guillermo\u00a0A et\u00a0al (2011) Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a\u00a0phase\u00a0II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 22:689\u2013695. https:\/\/doi.org\/10.1093\/annonc\/mdq416","journal-title":"Ann Oncol"},{"key":"2169_CR30","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.21037\/atm-20-6833","volume":"9","author":"H Hatic","year":"2021","unstructured":"Hatic\u00a0H, Sampat\u00a0D, Goyal\u00a0G (2021) Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med 9:1037\u20131037. https:\/\/doi.org\/10.21037\/atm-20-6833","journal-title":"Ann Transl Med"},{"key":"2169_CR31","doi-asserted-by":"publisher","first-page":"e002119","DOI":"10.1136\/jitc-2020-002119","volume":"9","author":"L Young","year":"2021","unstructured":"Young\u00a0L, Finnigan\u00a0S, Streicher\u00a0H et\u00a0al (2021) Ocular adverse events in PD\u20111 and PD-L1 inhibitors. J\u00a0Immunother Cancer 9:e2119. https:\/\/doi.org\/10.1136\/jitc-2020-002119","journal-title":"J Immunother Cancer"},{"key":"2169_CR32","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.currproblcancer.2021.100826","volume":"46","author":"N Denlinger","year":"2022","unstructured":"Denlinger\u00a0N, Bond\u00a0D, Jaglowski\u00a0S (2022) CAR T\u2011cell therapy for B\u2011cell lymphoma. Curr Probl Cancer 46:100826. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100826","journal-title":"Curr Probl Cancer"},{"key":"2169_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/bjophthalmol-2021-320814","volume":"107","author":"AA Mumtaz","year":"2023","unstructured":"Mumtaz\u00a0AA, Fischer\u00a0A, Lutfi\u00a0F et\u00a0al (2023) Ocular adverse events associated with chimeric antigen receptor T\u2011cell therapy: a\u00a0case series and review. Br J Ophthalmol 107:901\u2013905. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-320814","journal-title":"Br J Ophthalmol"},{"key":"2169_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s00347-022-01641-3","volume":"119","author":"C Schiemenz","year":"2022","unstructured":"Schiemenz\u00a0C, Kakkassery\u00a0V, Heindl\u00a0LM (2022) Standard Operating Procedure (SOP) zur Versorgung von peri- und intraokul\u00e4ren Lymphomen. Ophthalmol 119:692\u2013692. https:\/\/doi.org\/10.1007\/s00347-022-01641-3","journal-title":"Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02169-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T09:01:51Z","timestamp":1746608511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02169-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2169"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02169-4","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"type":"print","value":"2731-720X"},{"type":"electronic","value":"2731-7218"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Niederau, P.A.\u00a0Wawer Matos Reimer, A.\u00a0Rokohl und L.\u00a0Heindl geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}